LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.135 USD | -72.44% |
|
-4.79% | +21.37% |
| Market Cap | 192M 169M 156M 144M 273M 18.4B 278M 1.87B 727M 9.01B 722M 706M 31.26B | P/E 2026 * |
-1.36x | P/E 2027 * | -1.81x |
|---|---|---|---|---|---|
| Enterprise Value | 192M 169M 156M 144M 273M 18.4B 278M 1.87B 727M 9.01B 722M 706M 31.26B | EV / Sales 2026 * |
10.1x | EV / Sales 2027 * | 2.98x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -72.44% | -4.79% | - | - | 192M | |
| +0.90% | -2.21% | +73.55% | +129.52% | 56.71B | |
| -2.45% | -7.83% | +63.92% | +83.15% | 51.3B | |
| +0.01% | +4.18% | +20.52% | +469.95% | 25.26B | |
| +0.97% | -3.48% | -15.77% | -12.36% | 23.65B | |
| +3.93% | +3.35% | +43.09% | -2.47% | 18.69B | |
| +1.53% | +2.13% | +39.56% | -25.09% | 17.71B | |
| +2.34% | +12.50% | +224.02% | +380.99% | 17.7B | |
| -0.92% | +1.58% | +35.79% | - | 14.26B | |
| +0.90% | +0.83% | +27.79% | +195.31% | 14.1B | |
| Average | +0.47% | +4.02% | +56.94% | +152.37% | 26.6B | |
| Weighted average by Cap. | +0.39% | +2.20% | +58.35% | +143.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 19.03M 16.69M 15.41M 14.24M 26.99M 1.82B 27.53M 185M 71.99M 892M 71.47M 69.91M 3.1B | 64.52M 56.59M 52.25M 48.28M 91.51M 6.18B 93.34M 628M 244M 3.02B 242M 237M 10.5B |
| Net income | -141M -124M -114M -106M -200M -13.52B -204M -1.37B -534M -6.62B -530M -519M -22.97B | -109M -95.87M -88.51M -81.79M -155M -10.47B -158M -1.06B -413M -5.12B -410M -401M -17.78B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- LENZ Stock
- GRPH Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
